BioSpace News Archive

CytoDyn withdrew its pending Biologics License Application for leronlimab in HIV, citing concerns involving the contract research organization managing its trials.

Platform technology company Replay, based in San Diego and London, has launched Eudora, a gene therapy company targeting genetic diseases of the retina.

Monday, Actinium Pharmaceuticals released promising results Monday from a Phase III trial studying its lead radiotherapy candidate, Iomab-B, for patients with relapsed or refractory AML.

ESSA confirmed that Janssen has stepped away from a prostate cancer collaboration due to “operational recruitment challenges.”

On Nov. 16, the FDA’s Cardiovascular and Renal Drug Advisory Committee will meet to discuss the relative merits of Ardelyx’s tenapanor in chronic kidney disease.

While reporting stellar third-quarter financials, AbbVie announced it was halting development of cedirogant and provided updates on Skyrizi, Rinvoq and Humira.

The implications of the Inflation Reduction Act of 2022 (IRA) are beginning to show as Alnylam drops the Stargardt indication for vutrisiran and Sanofi’s CEO reassures investors.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented multiple datasets demonstrating persistent gene activation at the 6th International Conference on Epigenetics and Bioengineering, on October 29, 2022, in Houston, Texas.

Nicox SA, an international ophthalmology company, announced that once daily dosing of NCX 470 0.1% met the primary objective of non-inferiority in lowering intraocular pressure compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc Phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.

Theravance Biopharma, Inc. will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022.